Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 4 November 2026.
Announcements
6,263
Total raised
£165B
disclosed amounts
This month
£177M
raised so far
The late seed funding round was led by growth capital partner Fuel Ventures.
"Our mission is to bridge the information disconnect between the buyers and sellers of funds. Over the last 18 months, we’ve been working even closer with the wealth and asset management industry to do just that. Now, with Fuel’s investment and hands-on support we can continue to innovate, launch supporting tech platforms, and invest in the very best people."
The funding round was led by Barclays Sustainable Impact Capital and MEIF Proof of Concept and Early Stage Fund to support national expansion and job creation.
"Zedify’s model delivers tangible benefits- significant carbon reduction in the last mile; a fairer system for workers which counteracts the gig economy; cleaner, safer deliveries that contribute to healthier, more liveable cities; and more choice for consumers about how and when they receive their parcels. It’s exciting to have the backing of new and existing investors to enable us to realise our mission to transform urban logistics and create cities that are truly better for everyone."
Octopus Ventures led the series B round, which will help the digital therapeutics platform grow its footprint across the UK and Europe.
"HelloSelf is about giving everyone access to the personalised psychological advice they need. We want to help make Every Self Better. I’m delighted that Octopus has joined the mission. There are over 1.2Bn people who are underserved globally so with this investment and the trust of our network we can accelerate HelloSelf’s impact across the UK and beyond."
The £5.1m financing values the personal data platform at £30m and includes backing from high-profile figures such as Chris Gayle.
"We believe Gener8 is the first company in the world to enable people to centralise their data into one location and earn from it. We’ve built something that, until now, has only been theoretical in the world of academia"
Oppenheimer led the Series C financing, which will support US expansion and the development of new diagnostic tools.
"The second Series C second close further supports deployment, development and validation of our platform-based product portfolio targeted for clinical research and clinical use,"
